The progression of cancer is supported by a wide variety of non-neoplastic cell types which make up the tumour stroma, including immune cells, endothelial cells, cancerassociated fibroblasts and nerve fibres. These host cells contribute molecular signals that enhance primary tumour growth and provide physical avenues for metastatic dissemination. This article provides an overview of the role of blood vessels, lymphatic vessels and nerve fibres in the tumour microenvironment, and highlights the interconnected molecular signalling pathways that control their development and activation in cancer. Further the review highlights the known pharmacological agents which target these pathways and discusses the potential therapeutic uses of drugs that target angiogenesis, lymphangiogenesis and stress response pathways in the different stages of cancer care.
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The Tumour Microenvironment Influences Cancer Progression
The initiation and progression of cancer occurs in a microenvironment that consists of a broad range of non-neoplastic cells that make up the tumour stroma [1, 2] . The stroma comprises extracellular matrix, endothelial cells and pericytes, fibroblasts, mesenchymal stem cells, neural cells and immune cells including natural killer cells, macrophages and dendritic cells. The stroma connects to the broader circulatory system of blood and lymphatic vessels, and has receptors that make stromal cells responsive to signals from the peripheral autonomic nervous system ( Figure 1 ). In the peripheral tissues and within the tumour stroma, blood and lymphatic vessels exchange fluid and cells via specialised small capillaries while nerve fibres exchange molecular information via specialised synapses with other cell types. Together this collection of cells and matrix is the source of many important molecular signals that help to either promote or retard cancer growth and dissemination [3, 4] .
Prior to the initiation of cancer, normal human tissue is a highly ordered series of specialised cell types that function for a common purpose. Endothelial cells and nerve fibres share receptors for guidance cues that direct their growth and maturation [5] . During embryonic development, activation of these receptors results in common patterns of migratory behaviour by nerve fibres and blood vessels to support limb and muscle development [5] . In the adult this results in co-localization of nerve fibres, blood vessels and lymphatic vessels in neurovascular bundles. While related in their migratory passage into tissue, these three structures carry out diverse functions relating to tissue homeostasis. Blood vessels are part of the high pressure cardiovascular system that carries cells, protein-rich fluid and macromolecules to tissues. Arterial blood vessels connect to capillary beds where nutrients M A N U S C R I P T
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and waste products are exchanged from cells, and blood is then returned to the heart via veins. The function of the blood vasculature is complemented by lymphatic vessels that return cells and fluid from the interstitium back to the blood circulation [6] . Lymphatics start as small blind-ended vessels in the periphery which are known as initial lymphatics.
The initial lymphatic vessels within tissue drain into pre-collecting and collecting lymphatic vessels that empty into regional lymph nodes and finally transit extracellular fluid back into circulation via the thoracic duct. Peripheral tissues are innervated by efferent fibres from the sympathetic branch of the autonomic nervous system. Autonomic neurons play a critical role in maintaining physiological homeostasis. They receive information integrated in the central nervous system (CNS) and communicate this via vertebral ganglia to control functions that are largely involuntary including heart rate, blood pressure, temperature and digestion.
Ordered tissue architecture is disrupted during cancer development which affects the structure and function of local and distant blood and lymphatic vessels to accelerate cancer progression [6, 7] . This review describes the role of lymphatic and blood vessels in metastasis and characterizes physiological factors that regulate their function, including inflammation and neural signals from the sympathetic nervous system (SNS). We describe therapeutic approaches that target molecular mediators of angiogenesis, lymphangiogenesis, and neural signalling, and discuss how these pro-metastatic molecules might be targeted in new anti-cancer drug combinations or novel clinical settings.
Angiogenesis and lymphangiogenesis. New blood and lymphatic vessels can form in and
around tumours via the processes of angiogenesis and lymphangiogenesis, respectively [7] .
During angiogenesis, endothelial cells that line pre-existing blood vessels are released from the extracellular matrix to form tip cells which lead a stalk of proliferating endothelial cells M A N U S C R I P T
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to reform as a new vessel [8] . Angiogenesis and lymphangiogenesis play critical roles in epithelial tumour progression by facilitating key steps in metastasis including tumour cell escape from the primary tumour and metastatic colonization of distant organs [9] .
Metastasis is a complex multistep process that requires establishment of angiogenesis and evasion of the host immune defences for successful colonization of distant organs [10] .
Metastasis begins with local invasion of the surrounding parenchyma by cancer cells followed by intravasation into nearby blood or lymphatic vessels. Both angiogenesis and lymphangiogenesis contribute to metastasis by providing new blood capillaries and initial lymphatics that tumour cells can use as entry points for dissemination [11, 12] . Tumour cells may traffic through these vessels to distant lymph nodes or distant organs where metastasis requires extravasation into the surrounding parenchyma. Successful colonization depends on development of a micrometastasis and finally the formation of a macrometastasis with localized angiogenesis providing new tumour-associated vasculature [9] .
While much attention in recent times has been directed towards the formation of new vessels in a growing tumour, recent studies have also highlighted that molecular remodelling and re-differentiation of pre-existing vessels, without the formation of new vessels, contributes to metastasis [11, 13] . In response to angiogenic and lymphangiogenic stimuli, blood vessel capillaries and initial lymphatic vessels undergo sprouting angiogenesis and lymphangiogenesis, while larger blood and lymphatic vessels (eg. arteries or collecting lymphatics) undergo dilation and remodelling of the supporting smooth muscle cells. These changes in vascular structures promote increased lymph flow, dissemination of tumour cells and metastasis to regional lymph nodes [6, 12] .
Neural signalling. In response to stressful conditions, SNS nerve fibres convey information from the CNS to the periphery to mediate the flight-or-flight response to threat [14] .
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Increasing evidence indicates that these neural signals also remodel the tumour microenvironment in ways that promote cancer progression. SNS fibres innervate organs that support growth of primary and metastatic secondary tumours, including lung, liver, lymphoid tissues and bone marrow. Chronic stress induces the release of the catecholaminergic neurotransmitter noradrenaline from these nerve fibres and invokes systemic release of adrenaline from the adrenal medulla. Stress neurotransmitters bind beta-adrenergic receptors on target cells and induce a signalling cascade through cAMP synthesis and protein kinase A phosphorylation to modulate cellular transcriptional programs. In addition to regulating neurotransmitter release, chronic stress also remodels neural architecture to increase the density of nerve fibres in peripheral organs, which may serve to amplify adrenergic signalling in stressed individuals [15] . Beta-adrenergic receptors are present on tumour cells and stromal cells in the tumour microenvironment [16] [17] [18] [19] [20] , suggesting that tumour dynamics may be responsive to adrenergic stress response signalling.
In vivo studies have provided persuasive evidence that beta-adrenergic signalling promotes cancer progression. Beta-adrenergic activation by chronic physiological stress or by pharmacological beta-agonists increased spontaneous metastasis from primary mammary tumours to clinically relevant target organs including lymph node, lung and bone [20] [21] [22] [23] .
Adrenergic stress signalling had minimal effect on primary tumour growth rates in models of breast cancer [20, 30] 
The effect of chronic stress on cancer progression in patients has been more challenging to define. Epidemiological studies and a meta-analysis of 131 prospective studies linked chronic stress to progression of established breast cancers [32-38] and a psychosocial intervention that sought to buffer stress showed improved cancer-related outcomes [39, 40] .
However, few consistent relationships have been found between stress and the initial incidence of breast cancer [41] [42] [43] [44] [45] . Consistent with a key role for beta-adrenergic signalling in the pro-tumour effects of stress, recent epidemiological studies show that beta-blocker usage at the time of diagnosis is associated with improved outcomes in multiple tumour types (reviewed below, see Table 1 ). These studies highlight the emerging importance of stress response pathways in influencing cancer progression and suggest that effective disease management may include consideration of the whole patient, including their experience of chronic stress and other psychosocial factors. Lymphangiogenesis. Tumour cells and stromal cells secrete VEGF-C and VEGF-D which drive lymphangiogenesis or lymphatic remodelling in the tumour microenvironment. These growth factors can be proteolytically activated [65] [66] [67] [68] [69] leading to high-affinity binding of VEGFR-3 to promote lymphangiogenesis involving initial lymphatic vessels, and VEGFR-2 which promotes circumfirential expansion of initial lymphatics [7, [70] [71] [72] [73] [74] . VEGF-C and VEGF-D mediated lymphangiogenesis that promoted metastasis to lymph nodes [61, 62, 75 [88, 89] . Two COX isoforms are responsible for PG biosynthesis. COX-1 is constitutively expressed in most tissues and is important in maintaining basal PG levels, whereas COX-2 is induced in tissues during inflammation and cancer. Consequently, COX-2 is up-regulated by inflammatory mediators in many types of cancers including breast, colon, lung, pancreas, and head and neck cancers [90] [91] [92] [93] [94] [95] [96] [97] [98] . PG synthesis is balanced by 15-hydroxyprostaglandin dehydrogenase (PGDH), which degrades PG [99] . Expression of PGDH M A N U S C R I P T
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was shown to be abrogated in animal models of colon cancer suggesting that PGDH is a tumour suppressor [100] [101] [102] . The pro-tumourigenic effects of COX-2 are believed to be largely attributed to its role in producing PGE2 [103, 104] . PGE2 exerts its effects via prostaglandin E receptors (EP)1-4 G-protein coupled receptors [105] . Tumour studies conducted in EP receptor knockout animals or using pharmacological inhibition revealed that these receptors contribute to tumour angiogenesis and lymphangiogenesis [106] [107] [108] [109] [110] .
PGs are released by tumour cells and stromal cells, and play a central role in the tumour inflammatory response by down-regulating anti-neoplastic cytokines tumour necrosis factoralpha (TNF-α) and interferon-gamma (IFNγ) whilst up-regulating immunosuppressive cytokines including interleukin (IL)-10, IL-4 and IL-6 [111, 112] . PGE2 promotes tumour immunosuppression by inhibiting maturation of cytotoxic T cells [113] and increasing migration of dendritic cells to lymph nodes [114] . Naïve T cells fail to respond to tumourderived antigens presented by dendritic cells or antigen presenting cells, which enhances tumour cell evasion of host immune defences and permits metastatic dissemination through blood or lymphatic vasculature.
The link between the VEGF family members and inflammatory PG signalling pathways was first observed in animal models of colon cancer, where an association between COX-2, VEGF-A expression and angiogenesis was demonstrated [115, 116] . PG signalling by stromal cells including fibroblasts and endothelial cells was also shown to contribute to angiogenesis [108, 117, 118] . Clinical studies have demonstrated a correlation between the level of COX-2 expression and the extent of angiogenesis in breast, endometrial and gastric cancers [119] [120] [121] . Likewise, clinical and histopathological studies have revealed a correlation between COX-2 expression, lymphatic vessel density and lymph node metastasis in several human cancer types [122] [123] [124] . The PG pathway can influence lymphatic vessel density and therefore lymph node metastasis by regulating the levels of VEGF-C and VEGF-D produced M A N U S C R I P T
within both the tumour and tumour stroma [125] [126] [127] . PGE2 mediates this effect by acting via different EP receptors expressed on the surface of various tumour or stromal cells.
Activation of EP3 caused an increase in VEGF-C and VEGF-D secretion by cultured macrophages whereas EP4 activation elevated VEGF-C secretion by tumour-associated macrophages and VEGF-D secretion by tumour-associated fibroblasts leading to enhanced lymphangiogenesis within the primary tumour [127] . In addition, local secretion of PG by endothelial cells can also affect the morphology of the lymphatics by dilation and can facilitate the dissemination of cancer cells to draining lymph nodes [13] . These findings production by cultured macrophages [130] . Similarly, significant life stress prior to diagnosis M A N U S C R I P T
with ovarian cancer was associated with increased MMP9 production by CD68+ cells in primary tumours [130] , which has been associated with aggressive tumour progression likely due to altered basement membrane integrity.
The adverse effects of stress on angiogenesis may be reversed by alternate neurotransmitter signalling, although the clinical application of this is unclear. Dopamine was found to act on tumour cells and pericytes to reverse stress-induced angiogenesis and increase pericyte coverage to stabilize blood vessels [131] . The effect of stress response pathways on lymphangiogenesis has not been evaluated. However, beta-adrenergic regulation of both PG synthesis and normal lymphatic development and lymphatic flow [132, 133] suggest that neural signalling may regulate tumour-associated lymphangiogenesis.
In addition to modulating the tumour microenvironment, neural signalling may impact metastasis by directly modulating invasive, inflammatory and anti-apoptotic behavior by tumour cells. Tumour cells express beta-adrenergic receptors, and receptor levels have been associated with adverse outcomes [16, 17] . Beta-adrenergic signalling increases expression of inflammatory cytokines including IL-6 and IL-8 by tumour cells [19, 134] and drives invasion of cancer cells in culture assays [135] [136] [137] . Beta-adrenergic activation promoted ovarian cancer cell resistance to anoikis through focal adhesion kinase-mediated pathways [138] and protected cells against chemotherapy induced apoptosis [26, 139].
Drugs that Target Angiogenesis and Lymphangiogenesis
Anti-angiogenics and anti-lymphangiogenics. Various targeted anti-angiogenic agents have been approved by the U.S. Food and Drug Administration for clinical use in oncology, most of which target VEGF-A/VEGFR-2 signalling with varying degrees of specificity [140] (Figure 1 ).
The first was bevacizumab (also known as Avastin), a humanized neutralizing anti-VEGF-A M A N U S C R I P T
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monoclonal antibody used to treat multiple cancers, typically in combination with cytotoxic chemotherapy [141] . The observed lack of efficacy of bevacizumab as a single agent led to the suggestion that it may be more effectively utilized as a chemosensitization agent by enhancing entry of chemotherapeutics into tumours, consequent to bevacizumab-induced vascular normalization [142] .
Other anti-angiogenic agents in oncology include Aflibercept ("VEGF Trap"), a soluble receptor which binds VEGF-A, VEGF-B and PlGF, that was recently approved for treatment of metastatic colorectal cancer [143] . Various small molecule protein kinase inhibitors (PKIs) which target VEGFR-2 and other kinases have been approved, including pazopanib (Votrient), vandetanib (Zactima), sunitinib (Sutent) and sorafenib (Nexavar) [140] . PKIs typically target multiple kinases which can enhance efficacy but lead to side-effects. The resulting doselimiting toxicities have restricted PKI use in oncology due to difficulties combining PKIs with cytotoxic chemotherapeutics. A challenge associated with anti-angiogenic agents is emergence of drug resistance during treatment, hence considerable effort is being made to define mechanisms of resistance that may lead to improved treatment strategies [140, 144] NSAIDs. NSAIDs are a diverse group of drugs that have been traditionally used to treat inflammatory disease. These drugs alter PG levels by regulating the activity of COX enzymes and are used during surgery as analgesics and for pain management post-surgery. NSAIDs include selective inhibitors against COX-1 (eg. Ketoprofen) or COX-2 (eg. Celecoxib, Etodolac and Rofecoxib) or non-selective drugs that inhibit both COX enzymes (eg. Aspirin, Naproxen and Ibuprofen) [155] . While some experimental evidence suggested anti-cancer effects of NSAIDs, recent clinical trial data have shown a significant link between NSAID intake and restricted cancer development [115, [156] [157] [158] . Data further suggested this effect was at the level of preventing metastasis [159] .
By inhibiting PG synthesis, NSAIDs have profound effects on key characteristics of tumourigenesis, including cell proliferation, migration, apoptosis and angiogenesis [155] .
Epidemiologic studies found long-term use of NSAIDs was associated with reduced risk of breast, colon, lung and prostate cancer and recurrence [160] [161] [162] . Consistent with this, clinical trials revealed that NSAIDs restricted tumour progression in breast and prostate cancer patients [159, 161, [163] [164] [165] [166] . To define the cellular and molecular mechanisms by which NSAIDs restrict metastasis, the impact was assessed on both lymphangiogenic growth factor expression and structure of the lymphatic vasculature in pre-clinical models of metastatic disease. In vitro treatment of breast and esophageal cancer cell lines with Nimesulide, Diclofenac, Rofecoxib or SC-5600 induced a down-regulation of VEGF-C expression [167, 168] . In a model of gastric cancer, treatment with a COX-2 inhibitor, M A N U S C R I P T
Etodolac, reduced lymphangiogenesis which decreased metastasis to sentinel lymph nodes.
NSAIDs regulate lymphangiogenesis by reducing macrophage secretion of VEGF-C to modulate lymphatic vessel density and by modulating the morphology of lymphatic collector vessels that facilitated metastasis [13, 126, 169, 170] Beta-blockers. Beta-adrenergic regulation of cancer progression suggests that inhibiting adrenergic stress response pathways with beta-blockers might protect against metastasis and cancer progression. Sir James W. Black developed the beta-blocker propranolol in 1964 [171] and in 1975 founded the first clinical trial of beta-blockers for heart failure. Betablockade revolutionized the medical treatment of heart disease including hypertension, arrhythmias and angina, and is used peri-operatively to maintain physiological homeostasis.
Beta-blockers bind beta-adrenergic receptors and prevent activation by endogenous catecholaminergic neurotransmitters. Beta-blockers can therefore regulate the effects of SNS signalling on heart and smooth muscle contractility. Due to their ability to block stress neurotransmitter signalling at the cellular level, beta-blockers may also be a novel anticancer therapeutic strategy for targeted blockade of the stress responsive pathways.
The peri-operative period may be particularly sensitive to stress biology, and offer opportunity for novel application of NSAIDS and beta-blockers. Surgical stress increased retention of tumour cells in lung in rodent models of breast cancer [23, 31] and increased tumour growth in ovarian cancer models [172] . Induction of inflammation with PGE2 increased tumour cell retention and promoted an immunosuppressive environment by decreasing natural killer cell activity [31] . COX inhibitors and beta-blockers both reduced M A N U S C R I P T
tumour cell retention, but the effect was additive when the drugs were combined [31].
Combined Propranolol and Etodolac treatment also increased survival rates in mice following tumour excision [173] . NSAIDs and beta-blockers are already used in the perioperative setting to limit inflammation and regulate heart rate and blood pressure. These findings suggest that peri-operative use of NSAIDs in combination with beta-blockers may provide opportunities to improve immune competence and reduce the risk of tumour metastasis.
In addition to the pre-clinical studies described above indicating that beta-blockade slows progression of multiple tumour types, epidemiological studies suggest beta-blockers may protect patients against the progression of cancer. Many of these large retrospective cohort studies found that beta-blocker usage for co-morbid hypertension was associated with improved cancer-related outcomes, including increased metastasis-free survival and negative lymphovascular status [174, 175] (see Table 1 ). In contrast, use of other antihypertensive medications including angiotensin converting enzyme inhibitors or calcium channel blockers were not associated with beneficial effects [176] [177] [178] [179] [180] . Metoprolol and atenolol were the most frequently prescribed beta-blockers in these studies, followed by non-selective propranolol. Drug exposure varied with some studies looking at associations of beta-blocker usage prior to diagnosis while others investigated beta-blockade concurrent with neoadjuvant chemotherapy.
It is unclear if all beta-blockers protect equally against cancer progression. Pre-clinical studies suggest signalling through beta2-adrenergic receptors promote cancer progression but few studies have investigated the effect of signalling through beta1-or beta3-adrenergic receptors [24] . Antagonists that show mild selectivity towards beta1-adrenergic receptor including metoprolol and atenolol (2-5 fold selectivity for beta1 over beta2-adrenergic M A N U S C R I P T
receptors) are now more frequently prescribed than the older generation of non-specific beta-blockers. It will be critical to define receptors that mediate beta-adrenergic effects on cancer prior to randomized clinical trials. Similarly, not all tumour types may be equally responsive to beta-blockade. Beta-blocker use was associated with favorable outcomes in women with triple negative breast cancer [174, 175] , but not those with ER+ cancer. Betablocker use was associated with reduced prostate-cancer specific mortality in men who received androgen deprivation therapy, but not in those with androgen refractive tumours [181, 182] . Randomized trials of target populations will be required to validate these observations, however, they suggest that adrenergic signalling may interact with other signalling pathways in tumours to affect progression.
Future Directions
The bidirectional relationship between tumour cells and their microenvironment provides 
RESEARCH AND CLINICAL AGENDA
• Beta-blockers and NSAIDS may complement existing anti-angiogenesis strategies to treat cancer.
• Further research is required to define the receptors and signalling pathways that mediate these effects and windows of therapeutic opportunity • An unbiased evaluation of beta-blockers to treat cancer requires randomized clinical trials in defined patient populations. 
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